Cannabis and Migraine
Observational data suggest acute benefit, but no large RCTs support cannabis as a migraine treatment.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
Cannabis has a 150-year history in migraine care and modern observational data consistently point to acute pain relief. But there are no large, blinded randomized trials—and that matters more than history or anecdote. Standard migraine drugs (triptans, CGRP antibodies) have far stronger evidence. Cannabis might be worth discussing with a headache specialist if those don't work for you, but frequent use risks the exact problem you're trying to solve: medication-overuse headache.
Not Medical Advice
This article is not medical advice. It is a plain-language summary of published evidence. Migraine has many subtypes and overlaps with conditions (stroke, intracranial hypertension, medication overuse) that require diagnosis by a clinician. If you have new, severe, or changing headaches, see a doctor. If you are considering cannabis for migraine, discuss it with a neurologist or headache specialist, especially if you take triptans, SSRIs/SNRIs, or anticoagulants.
Plain-Language Summary
Migraine is a neurological disorder, not just a bad headache. Cannabis has been used for migraine for at least 150 years—Sir William Osler called Indian hemp "probably the most satisfactory remedy" for migraine in his 1892 textbook.
Modern research is much thinner than that history suggests. As of October 2026:
- A handful of small observational studies and patient surveys suggest inhaled cannabis reduces acute migraine pain intensity Weak / limited [1][2].
- One small randomized crossover trial (Nabilone vs. ibuprofen for medication-overuse headache) showed benefit Weak / limited [3].
- No large, high-quality randomized controlled trials exist for migraine prevention.
- Documented risk of medication-overuse headache with frequent use Strong evidence [4].
The American Headache Society and American Academy of Neurology do not include cannabis in their evidence-based treatment guidelines [5]. That's not because it's been proven not to work—it's because it hasn't been adequately tested in rigorous trials.
What Probably Works
Honestly, nothing about cannabis for migraine reaches "probably works" by rigorous standards. No treatment currently meets that bar.
The closest signal:
Inhaled THC-dominant cannabis reduces self-reported acute headache/migraine pain intensity in the short term. A 2020 analysis of 12,293 cannabis use sessions logged in the Strainprint app found approximately 50% reduction in self-rated headache severity, with diminishing returns over repeated use Weak / limited [1]. A separate 2016 survey of 121 adults found 85% reported improvement in migraine severity Weak / limited [2].
These findings are observational, unblinded, and selection-biased (people who don't get relief stop logging or using). They should not be confused with proof of efficacy. But they are the largest datasets we have and they consistently point in the same direction.
What Might Work
Nabilone (synthetic THC) for medication-overuse headache. A 2012 double-blind crossover trial in 30 patients found nabilone 0.5 mg outperformed ibuprofen 400 mg on pain intensity and analgesic dependence Weak / limited [3]. This is a single small trial; replication is needed. Nabilone is available as Cesamet (Nabilone) in some jurisdictions.
THC:CBD combinations for migraine prevention. Historical references cite a 2017 Italian conference presentation reporting a 200 mg/day THC:CBD combination reduced migraine frequency comparably to amitriptyline. This presentation was never published as a full peer-reviewed article, making it impossible to assess methodology or reproduce results Weak / limited. We note it because it is frequently cited in discussion of cannabis for migraine, but citation without publication is not a reliable evidence base.
CBD alone. Despite heavy marketing, there is essentially no controlled trial data on isolated CBD for migraine No data. Mechanistic plausibility exists (potential anti-inflammatory effects, possible modulation of CGRP signaling), but mechanism does not substitute for evidence.
What Doesn't Work or Has Weak Evidence
"Indica vs. sativa" for migraine relief. The indica/sativa dichotomy does not reliably predict cannabinoid composition or effects Disputed. Strain name is a poor predictor of outcome.
Specific "migraine strains." Dispensary recommendations for cultivars such as Harlequin, ACDC, or OG Kush for migraine are based entirely on customer reports, not controlled trials Anecdote.
Topical CBD for migraine. No meaningful evidence exists No data. Migraine is a central nervous system event; topical cannabinoids do not reach therapeutic brain concentrations.
The "clinical endocannabinoid deficiency" hypothesis as established cause. Ethan Russo proposed that clinical endocannabinoid deficiency (CECD) may underlie migraine, fibromyalgia, and irritable bowel syndrome [6]. Some supporting evidence exists—lower cerebrospinal fluid anandamide levels have been found in chronic migraineurs—but CECD remains a hypothesis, not established pathophysiology Weak / limited.
What We Don't Know
- Optimal dose, cannabinoid ratio, or route of administration for migraine.
- Whether cannabis prevents migraines or only treats acute attacks.
- Long-term efficacy beyond weeks to months; tolerance is a documented concern with regular use.
- Whether CBD monotherapy has any migraine-specific benefit.
- Interactions with newer CGRP monoclonal antibody preventatives (erenumab, fremanezumab, galcanezumab, eptinezumab)—the standard-of-care class for moderate-to-severe migraine prevention.
- Whether positive signals in observational studies will survive rigorous, double-blind randomized trials. Cannabis has strong subjective and psychoactive effects that notoriously break blinding in clinical trials.
- Risk profile in pregnancy beyond general adverse associations.
Comparison With Standard Treatments
Evidence-based migraine treatments with strong randomized trial support [5]:
Acute attack: Triptans (sumatriptan, rizatriptan, frovatriptan, etc.), CGRP receptor antagonists or "gepants" (rimegepant, ubrogepant), ditans (lasmiditan), NSAIDs, and antiemetics. Triptans achieve pain-free status in 50–70% of treated attacks Strong evidence.
Prevention (chronic migraine or high-frequency episodic): CGRP monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab), topiramate, propranolol, amitriptyline, and onabotulinumtoxinA for chronic migraine ≥15 headache days/month Strong evidence.
Cannabis has not been compared head-to-head with any of these in adequately powered randomized trials. A practical framing: if standard treatments work for you, there is no strong reason to switch. If they don't work, cause intolerable side effects, or you have contraindications, cannabis is one of several adjuncts worth discussing with a specialist—alongside nerve blocks, neuromodulation devices (transcranial magnetic stimulation, TENS), and supplements with weak-to-moderate evidence (riboflavin, magnesium, CoQ10).
Risks
Medication-overuse headache (MOH). Any acute migraine medication used >10–15 days/month can paradoxically cause chronic daily headache. Cannabis is no exception. A 2021 study found cannabis users with chronic migraine had significantly higher rates of medication-overuse headache than non-users Strong evidence [4]. This is a real risk with frequent self-medication.
Cannabinoid hyperemesis syndrome (CHS). Cyclic vomiting and nausea in heavy, long-term users—easily misdiagnosed as migraine with nausea, and the treatment (cessation) is the opposite of what a migraineur might choose Strong evidence.
Drug interactions. THC and CBD inhibit CYP3A4 and other hepatic enzymes. Clinically relevant interactions can occur with antidepressants (SSRIs, tricyclics), anticonvulsants (topiramate, valproate), and blood thinners used concurrently for migraine prevention or other indications Strong evidence. See Cannabis and Polypharmacy Risks.
Cardiovascular risk. Migraine with aura already confers elevated ischemic stroke risk. Cannabis use is associated with increased risk of ischemic stroke in young adults, particularly with heavy or daily use Weak / limited [7].
Cognitive impairment. Frequent THC use affects attention, memory, and processing speed. For people whose migraines are already cognitively or occupationally disabling, adding cannabis-related cognitive effects may worsen overall function.
Pregnancy. Avoid completely. Cannabis use in pregnancy is associated with adverse fetal outcomes and no migraine treatment should be self-initiated during pregnancy Strong evidence [8].
Bottom Line
Cannabis for migraine is neurologically plausible, has a long historical footprint, shows consistent positive signals in observational data, and lacks the randomized trials required for evidence-based guideline endorsement. If standard therapies are failing you, it is a reasonable conversation to have with a headache specialist—particularly one who will neither dismiss it reflexively nor oversell it as a proven treatment.
If you do try cannabis, use caution with frequency. Daily or near-daily use risks crossing into medication-overuse headache territory without obvious warning. Discuss interactions with any other migraine medications you take, and do not use if you are pregnant or have cardiovascular risk factors. A specialist can help you weigh the weak evidence against your individual migraine phenotype and comorbidities.
Sources
- Peer-reviewed Cuttler C, Spradlin A, Cleveland MJ, Craft RM. Short- and long-term effects of cannabis on headache and migraine. Journal of Pain. 2020;21(5-6):722–730.
- Peer-reviewed Rhyne DN, Anderson SL, Gedde M, Borgelt LM. Effects of medical marijuana on migraine headache frequency in an adult population. Pharmacotherapy. 2016;36(5):505–510.
- Peer-reviewed Pini LA, Guerzoni S, Cainazzo MM, et al. Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial. Journal of Headache and Pain. 2012;13(8):677–684.
- Peer-reviewed Zhang N, Woldeamanuel YW. Medication overuse headache in patients with chronic migraine using cannabis: a case-referent study. Headache. 2021;61(8):1234–1244.
- Peer-reviewed Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021–1039.
- Peer-reviewed Russo EB. Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis and Cannabinoid Research. 2016;1(1):154–165.
- Peer-reviewed Alsherbiny MA, Li CG. Medicinal cannabis—potential drug interactions. Medicines. 2018;6(1):3.
- Peer-reviewed Hemachandra D, McKetin R, Cherbuin N, Anstey KJ. Heavy cannabis users at elevated risk of stroke: evidence from a general population survey. Australian and New Zealand Journal of Public Health. 2016;40(3):226–230.
- Government American College of Obstetricians and Gynecologists Committee Opinion No. 722: Marijuana use during pregnancy and lactation. Obstetrics & Gynecology. 2017;130(4):e205–e209.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- Cannabis and Sleep Architecture — How cannabinoids alter sleep stages, what works short-term, why tolerance develops, and sa...
- Cesamet (Nabilone) — Synthetic THC approved for refractory chemotherapy nausea; off-label use varies in evidenc...